Immunocore reports third quarter financial results and provides a business update
Globe Newswire•06/11/2026•09:00 ET
0
Key Highlights
- ➤KIMMTRAK Q3 net revenue $102.2 million; underlying revenue growth approximately 10%
- ➤Nine-month KIMMTRAK net sales $324.8 million, up from $295.5 million
- ➤TEBE-AM Phase 3 trial completed enrollment of 540 patients; topline OS data expected Q2 2027
- ➤Cash, equivalents and marketable securities reached $901.3 million as of September 30, 2026
- ➤First type 1 diabetes patient dosed in Phase 1 trial of IMC-S118AI
Expert Statements
Bahija Jallal, CEO of Immunocore
“Nearly five years after launch, KIMMTRAK remains the proven standard of care in HLA-A*02:01+ metastatic uveal melanoma. With TEBE-AM fully enrolled and data expected in the second quarter of 2027, we are advancing our mission to bring this therapy to even more patients”
Bahija Jallal, CEO of Immunocore
“Recently, our platform delivered two significant firsts: what we believe is the first data demonstrating clinical activity and a manageable safety profile with the combination of two T cell engagers in a solid tumor, and the first patient dosed in our tissue-specific autoimmune program for type 1 diabetes.”
KIMMTRAK(®) (tebentafusp-tebn) net revenues of $102.2 million in Q3 2026 and net revenues of $324.8 million for the first nine months of 2026, representing 10% year-over-year growth year to date
Phase 3 TEBE-AM trial for previously treated advanced cutaneous melanoma completed target enrollment of 540 patients – Topline overall survival data expected second quarter of 2027
Get started
Create a free account to read the full story.